Rockwell Medical stock: $125 million Vantive deal targets mid-2027 close

Published on 11/06/2026 at 00:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rockwell Medical stock is set to expand its dialysis portfolio through a proposed Vantive acquisition. Closing is expected in mid-2027.

Deal and next steps

Rockwell Medical agreed to acquire Vantive hemodialysis assets and related operations.
The transaction still requires regulatory approvals and other closing conditions.
Rockwell Medical is scheduled to report third-quarter results on November 12.

RMTI, US7743743004, Illustration mit AI erstellt.

Rockwell Medical announced on Tuesday, November 3, 2026, that it had entered an agreement to acquire Vantive's global hemodialysis business. Yahoo Finance reported that the transaction covers hemodialysis concentrates, machines, water treatment systems, related consumables and technical services.

Acquisition broadens dialysis offering

The agreement includes Vantive's AK-98 hemodialysis machines and the Medolla manufacturing campus in Italy. Vantive's dialyzer portfolio, including Theranova, is excluded from the transaction.

The base purchase price is 125 million US dollars, subject to customary adjustments. Financing is structured through two 50 million US dollar term loans from Vantive and a 25 million US dollar convertible note. Vantive may also receive up to 45 million US dollars in contingent consideration tied to specified revenue and EBITDA milestones.

Closing remains a future catalyst

The companies expect the transaction to close in mid-2027, subject to regulatory approvals and other conditions. Rockwell Medical's next scheduled operating milestone is the release of third-quarter results on Thursday, November 12, 2026, followed by an investor webcast.

Rockwell Medical business profile

Rockwell Medical is a Wixom, Michigan-based healthcare company focused on chronic and end-stage kidney disease. It develops and supplies Triferic iron replacement therapies, hemodialysis concentrates and ancillary products used by dialysis providers. Its customers include medium-sized and small dialysis chains as well as independent dialysis centers in the United States and international markets.